Novel Molecular Multilevel Targeted Antitumor Agents

about

White paper on microbial anti-cancer therapy and prevention

P2860

Q56898750-2218DA3A-11B3-43AE-9770-DEBC26D0DA3E

P2860

Novel Molecular Multilevel Targeted Antitumor Agents

Item

http://www.wikidata.org/entity/Q41429679

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Novel Molecular Multilevel Targeted Antitumor Agents

@en

type

Item

label

Novel Molecular Multilevel Targeted Antitumor Agents

@en

prefLabel

Novel Molecular Multilevel Targeted Antitumor Agents

@en

P1476

Novel Molecular Multilevel Targeted Antitumor Agents

@en

P2093

Denise M Herpai

http://www.w3.org/2001/XMLSchema#string

Hetal Pandya

http://www.w3.org/2001/XMLSchema#string

Izabela Fokt

http://www.w3.org/2001/XMLSchema#string

Poonam Sonawane

http://www.w3.org/2001/XMLSchema#string

Waldemar Debinski

http://www.w3.org/2001/XMLSchema#string

Waldemar Priebe

http://www.w3.org/2001/XMLSchema#string

Young A Choi

http://www.w3.org/2001/XMLSchema#string

P2860

The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1

New developments for antibody-drug conjugate-based therapeutic approaches

Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain

Expression of the lysosomal-associated membrane protein-1 (LAMP-1) in astrocytomas

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

P304

69-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/CTM.CTM_12_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28825042

http://www.w3.org/2001/XMLSchema#string

P932

5558462

http://www.w3.org/2001/XMLSchema#string

Novel Molecular Multilevel Targeted Antitumor Agents

about

P2860

P2860

Novel Molecular Multilevel Targeted Antitumor Agents

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932